Common adverse events on treatment were fatigue, dry mouth, nausea, anaemia, decreased appetite and constipation. The FDA also approved a complementary diagnostic imaging agent, gallium Ga 68 gozetotid, to identify PSMA-positive lesions.doi:10.1038/d41573-022-00067-5Asher Mullard...
Lutetium-177-PSMA-617 is now FDA-approved for the treatment of patients with metastatic castration-resistant prostate cancer who have already received androgen receptor pathway inhibition and taxane-based chemotherapy. The FDA has approved lutetium-177 (177Lu)-PSMA-617 (Pluvicto) to treat patien...
On March 23, 2022, the FDA approved Lu 177 vipivotide tetraxetan for the treatment of adult patients with PSMA-positive mCRPC who have previously received AR pathway inhibition and taxane-based chemotherapy, also based on findings from the VISION trial.3 To be eligible for enrollment in the st...
As for the initial tumor, the higher the Gleason score, the higher the detection rate [29]. In addition, some prospective investigations found that PSMA PET/CT changed the course of treatment in 64–68% of patients after BCR, indicating a significant impact on the selection of treatment optio...
FDA approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. April ...
Metastatic prostate cancer has a 5-year survival rate of less than 30%3; mCRPC patients who progress on multiple lines of therapy have limited treatment options FDA approval was based on pivotal Phase III VISION trial, where patients with pre-treated PSMA-positive mCRPC who recei...
Metastatic prostate cancer has a 5-year survival rate of less than 30%3; mCRPC patients who progress on multiple lines of therapy have limited treatment options FDA approval was based on pivotal Phase III VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plu...
Radioligand therapy (RLT) agents are demonstrating a crucial role in the clinical approach to aggressive malignancies such as metastatic castrate-resistant prostate cancer (m-CRPC). With the recent FDA approval of prostate-specific membrane antigen (PSMA)-targeted RLT for m-CRPC, the field has br...
“Ga 68 PSMA-11 is an important tool that can aid health care providers in assessing prostate cancer,” Alex Gorovets, MD, acting deputy director of the Office of Specialty Medicine in FDA’s Center for Drug Evaluation and Research, said in press releasee. “With this first approval of a...
T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting. What New Cancer Drugs Were Approved in 2023? Lindsay Fischer ...